Baudax Bio Profit Margin

The latest profit margin for BXRX is -2201.54% as of September 2023. That compares with -1656.84% in the prior-year period — down 32.9% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Baudax Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, BXRX's profit margin moved from -1656.84% to -2201.54% — a 32.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Baudax Bio's valuation or profitability profile.

Against Healthcare companies, BXRX currently prints -2201.54% for profit margin, while the sector average sits near 15.29%. That is roughly 14495.8% below the sector mean. Large gaps often invite a closer look at Baudax Bio's growth, margins, and balance sheet.

Profit Margin shows how effectively Baudax Bio converts resources into returns. At -2201.54%, BXRX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1656.84% in the prior-year period — down 32.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BXRX's profit margin (-2201.54%), review year-over-year change from -1656.84%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.